Next month the FDA is hosting a public advisory committee meeting to discuss a change to the intended use of Dexcom's G5 Mobile Continuous Glucose Monitoring System (CGM) device that would allow the ...
The Food and Drug Administration (FDA) has expanded the use of Dexcom's G5 Mobile Continuous Glucose Monitoring (CGM) System to allow for replacement of blood glucose testing for diabetes treatment ...
A new diabetes device may make tracking blood sugars and taking medication easier. The U.S. Food and Drug Administration said Tuesday that the Dexcom G5 continuous glucose monitoring system (CGM) can ...
Please provide your email address to receive an email when new articles are posted on . The FDA recently approved an expanded indication for DexCom’s G5 Mobile Continuous Glucose Monitoring System to ...
For the first time, the US Food and Drug Administration has approved the use of a continuous glucose monitoring (CGM) system to replace finger-stick testing for determining insulin doses. The decision ...
Dexcom is looking for the agency to let patients use the device without the confirmation of a finger stick before treatment. The G5 CGM system includes a glucose sensor, a transmitter that sends the ...
Share price of DexCom, Inc. DXCM jumped 4.8% on Aug 25, following the FDA approval of the DexCom G5 Mobile Continuous Glucose Monitoring (CGM) System. The fully portable product is the first and ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results